This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Samuelian, J.C. Articles by Hackett, D. Search for Related Content PubMed PubMed Citation Articles by Samuelian, J.C. Articles by Hackett, D. Social Bookmarking                         What's this?

A randomized, double-blind, parallel-group comparison of venlafaxine and clomipramine in outpatients with major depression

CHU Timone, Marseille

David Hackett

Wyeth Clinical Research and Development, Paris, France

A multicentre, randomized, double-blind study was conducted to compare the safety and antidepressant efficacy of venlafaxine and clomipramine in 102 outpatients with major depression. The patients received either venlafaxine or clomipramine at a dose titrated from 50 mg to a maximum of 150 mg/day during the first 2 weeks of treatment. Treatment was continued for up to 43 days. Montgomery Asberg Depression Rating Scale (MADRS) and Hamilton Depression Rating Scale (HAM-D) scores decreased significantly (p 0.05) from baseline in each treatment group but were not significantly different between groups. Response rates on the MADRS and HAM-D were 62% and 59%, respectively, with venlafaxine and 54% and 43%, respectively, with clomipramine. Treatment-emergent study events were the primary reason for withdrawal in only 13% of venlafaxine-treated patients and 20% of clomipramine-treated patients. On questionnaires, the incidence of anticholinergic-type events was 60% with venlafaxine and 68% with clomipramine. However, significantly (p=0.043) more patients in the clomipramine group reported multiple anticholinergic events than in the venlafaxine group. In the clomipramine group, mean ventricular heart rate increased significantly (p=0.003) and mean systolic blood pressure decreased significantly (p=0.028) from baseline, but no clinically significant electrocardiographic changes were observed. These results confirm the efficacy and safety of venlafaxine in the treatment of outpatients suffering from major depression.

Key Words: acute treatment • clinical trial • clomipramine • major depression • outpatients • venlafaxine

Journal of Psychopharmacology, Vol. 12, No. 3, 273-278 (1998)
DOI: 10.1177/026988119801200307


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				W. van den Broek, P. Mulder, E van Os, T. Birkenhager, E Pluijms, and J. Bruijn Efficacy of venlafaxine compared with tricyclic antidepressants in depressive disorder: a meta-analysis J Psychopharmacol, August 1, 2009; 23(6): 708 - 713. [Abstract] [PDF]

				D. SMITH, C. DEMPSTER, J. GLANVILLE, N. FREEMANTLE, and I. ANDERSON Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis The British Journal of Psychiatry, May 1, 2002; 180(5): 396 - 404. [Abstract] [Full Text] [PDF]

				J. K. Melichar, A. Haida, C. Rhodes, A. H. Reynolds, D. J. Nutt, and A. L. Malizia Venlafaxine occupation at the noradrenaline reuptake site: in-vivo determination in healthy volunteers J Psychopharmacol, January 1, 2001; 15(1): 9 - 12. [Abstract] [PDF]